The year had a lot to offer, from advanced therapies aimed at Lp(a), GLP-1, and other targets, to support for simpler ...
Hangzhou Sino-US Huadong Medicine Co., Ltd. (hereinafter referred to as "Huadong Medicine"), a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963), and SynerK PharmaTech (Suzhou) Co., ...
Huadong Medicine & SynerK ink strategic cooperation to jointly develop novel siRNA drug SNK-2726 targeting AGT to treat hypertension: Suzhou, China Monday, December 30, 2024, 17:0 ...